PEBP2-2/CBF-2 dependent phosphorylation of RUNX1 and p300 by HIPK2: Implications for leukemogenesis

Blood

Volumn 112, Issue 9, 2008, Pages 3777-3787

  Wee, Hee Jun ^a   Voon, Dominic Chih Cheng ^a   Bae, Suk Chul ^b   Ito, Yoshiaki ^a,c  

^a INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^b Chungbuk National University   (South Korea)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CORE BINDING FACTOR BETA; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; PROTEIN P300; TRANSCRIPTION FACTOR RUNX1; CARRIER PROTEIN; CBFB PROTEIN, HUMAN; CCAAT BINDING FACTOR; HIPK2 PROTEIN, HUMAN; HISTONE ACETYLTRANSFERASE PCAF; MULTIPROTEIN COMPLEX; PRIMER DNA; PROTEIN SERINE THREONINE KINASE; RECOMBINANT PROTEIN; RUNX1 PROTEIN, HUMAN;

ANIMAL CELL; ARTICLE; CELL STRAIN COS7; CELL STRAIN HEK293; CONTROLLED STUDY; GENE TARGETING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; ANIMAL; CELL STRAIN COS1; CELL STRAIN K 562; CERCOPITHECUS; CHEMISTRY; GENE DELETION; GENETICS; LEUKEMIA; METABOLISM; MOUSE; PHOSPHORYLATION; PROTEIN TERTIARY STRUCTURE; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

ANIMALS; BASE SEQUENCE; CARRIER PROTEINS; CCAAT-BINDING FACTOR; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CORE BINDING FACTOR BETA SUBUNIT; COS CELLS; DNA PRIMERS; HUMANS; K562 CELLS; LEUKEMIA; MICE; MULTIPROTEIN COMPLEXES; MUTAGENESIS, SITE-DIRECTED; P300-CBP TRANSCRIPTION FACTORS; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; PROTEIN-SERINE-THREONINE KINASES; RECOMBINANT PROTEINS; SEQUENCE DELETION;

EID: 55749091957     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-01-134122     Document Type: Article

References (57)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science. 1997;278:1059-1064.
2. Speck NA, Gilliland DG. Core-binding factors in haematopoiesis and leukaemia. Nat Rev Cancer. 2002;2:502-513.
3. Ito Y. RUNX genes in development and cancer: regulation of viral gene expression and the discovery of RUNX family genes. Adv Cancer Res. 2008;99:33-76.
4. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996;84:321-330.
5. Wang Q, Stacy T, Miller JD, et al. The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996;87:697-708.
6. Niki M, Okada H, Takano H, et al. Hematopoiesis in the fetal liver is impaired by targeted mutagenesis of a gene encoding a non-DNA binding subunit of the transcription factor, polyomavirus enhancer binding protein 2/core binding factor. Proc Natl Acad Sci U S A. 1997;94:5697-5702.
7. Ichikawa M, Asai T, Saito T, et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med. 2004;10:299-304.
8. Growney JD, Shigematsu H, Li Z, et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood. 2005;106:494-504.
9. Putz G, Rosner A, Nuesslein I, Schmitz N, Buchholz F. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene. 2006;25:929-939.
10. Motoda L, Osato M, Yamashita N, et al. Runx1 protects hematopoietic stem/progenitor cells from oncogenic insult. Stem Cells. 2007;25:2976-2986.
11. Huang G, Shigesada K, Ito K, Wee HJ, Yokomizo T, Ito Y. Dimerization with PEBP2beta protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 2001;20:723-733.
12. Li LH, Gergen JP. Differential interactions between Brother proteins and Runt domain proteins in the Drosophila embryo and eye. Development. 1999;126:3313-3322.
13. Sakuma T, Li QL, Jin Y, et al. Cloning and expression pattern of a novel PEBP2 beta-binding protein (charged amino acid rich leucine zipper-1[Crl-1]) in the mouse. Mech Dev. 2001;104:151-154.
14. Yoshida N, Ogata T, Tanabe K, et al. Filamin Abound PEBP2beta/CBFbeta is retained in the cytoplasm and prevented from functioning as a partner of the Runx1 transcription factor. Mol Cell Biol. 2005;25:1003-1012.
15. Watanabe T, Yoshida N, Satake M. Biological implications of filamin A-bound PEBP2beta/CBFbeta retention in the cytoplasm. Crit Rev Eukaryot Gene Expr. 2005;15:197-206.
16. Kim WY, Sieweke M, Ogawa E, et al. Mutual activation of Ets-1 and AML1 DNA binding by direct interaction of their autoinhibitory domains. EMBO J. 1999;18:1609-1620.
17. Petrovick MS, Hiebert SW, Friedman AD, Hetherington CJ, Tenen DG, Zhang DE. Multiple functional domains of AML1: PU.1 and C/EBPalpha synergize with different regions of AML1. Mol Cell Biol. 1998;18:3915-3925.
18. Hess J, Porte D, Munz C, Angel P. AP-1 and Cbfa/runt physically interact and regulate parathyroid hormone-dependent MMP13 expression in osteoblasts through a new osteoblast-specific element 2/AP-1 composite element. J Biol Chem. 2001;276:20029-20038.
19. Elagib KE, Racke FK, Mogass M, Khetawat R, Delehanty LL, Goldfarb AN. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-4341.
20. Asou N, Yanagida M, Huang L, et al. Concurrent transcriptional deregulation of AML1/RUNX1 and GATA factors by the AML1-TRPS1 chimeric gene in t(8;21)(q24;q22) acute myeloid leukemia. Blood. 2007;109:4023-4027.
21. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. EMBO J. 1998;17:2994-3004.
22. Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y. AWW domain-containing yes-associated protein (YAP) is a novel transcriptional coactivator. EMBO J. 1999;18:2551-2562.
23. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 2001;20:7184-7196.
24. Levanon D, Goldstein RE, Bernstein Y, et al. Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A. 1998;95:11590-11595.
25. Imai Y, Kurokawa M, Tanaka K, et al. TLE, the human homolog of groucho, interacts with AML1 and acts as a repressor of AML1-induced transactivation. Biochem Biophys Res Commun. 1998;252:582-589.
26. Chakraborty S, Sinha KK, Senyuk V, Nucifora G. SUV39H1 interacts with AML1 and abrogates AML1 transactivity: AML1 is methylated in vivo. Oncogene. 2003;22:5229-5237.
27. Lutterbach B, Westendorf JJ, Linggi B, Isaac S, Seto E, Hiebert SW. A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem. 2000;275:651-656.
28. Aikawa Y, Nguyen LA, Isono K, et al. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J. 2006;25:3955-3965.
29. Lu J, Maruyama M, Satake M, et al. Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF. Mol Cell Biol. 1995;15:1651-1661.
30. Zhang YW, Bae SC, Huang G, et al. A novel transcript encoding an N-terminally truncated AML1/PEBP2 alphaB protein interferes with transactivation and blocks granulocytic differentiation of 32Dcl3 myeloid cells. Mol Cell Biol. 1997;17:4133-4145.
31. Kanno Y, Kanno T, Sakakura C, Bae SC, Ito Y. Cytoplasmic sequestration of the polyomavirus enhancer binding protein 2 (PEBP2)/core binding factor alpha (CBFalpha) subunit by the leukemiarelated PEBP2/CBFbeta-SMMHC fusion protein inhibits PEBP2/CBF-mediated transactivation. Mol Cell Biol. 1998;18:4252-4261.
32. Osato M, Asou N, Abdalla E, et al. Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood. 1999;93:1817-1824.
33. Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364-1372.
34. Huang G, Shigesada K, Wee HJ, Liu PP, Osato M, Ito Y. Molecular basis for a dominant inactivation of RUNX1/AML1 by the leukemogenic inversion 16 chimera. Blood. 2004;103:3200-3207.
35. Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284-4296.
36. Tanaka T, Kurokawa M, Ueki K, et al. The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol. 1996;16:3967-3979.
37. Zhang Y, Biggs JR, Kraft AS. Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem. 2004;279:53116-53125.
38. Becker W, Weber Y, Wetzel K, Eirmbter K, Tejedor FJ, Joost HG. Sequence characteristics, subcellular localization, and substrate specificity of DYRK-related kinases, a novel family of dual specificity protein kinases. J Biol Chem. 1998;273:25893-25902.
39. Hofmann TG, Mincheva A, Lichter P, Droge W, Schmitz ML. Human homeodomain-interacting protein kinase-2 (HIPK2) is a member of the DYRK family of protein kinases and maps to chromosome 7q32-q34. Biochimie. 2000;82:1123-1127.
40. Castilla LH, Wijmenga C, Wang Q, et al. Failure of embryonic hematopoiesis and lethal hemorrhages in mouse embryos heterozygous for a knocked-in leukemia gene CBFB-MYH11. Cell. 1996;87:687-696.
41. Yergeau DA, Hetherington CJ, Wang Q, et al. Embryonic lethality and impairment of haematopoiesis in mice heterozygous for an AML1-ETO fusion gene. Nat Genet. 1997;15:303-306.
42. Liu P, Tarle SA, Hajra A, et al. Fusion between transcription factor CBF beta/PEBP2 beta and a myosin heavy chain in acute myeloid leukemia. Science. 1993;261:1041-1044.
43. Shigesada K, van de Sluis B, Liu PP. Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11. Oncogene. 2004;23:4297-4307.
44. Ikebe M, Komatsu S, Woodhead JL, et al. The tip of the coiled-coil rod determines the filament formation of smooth muscle and nonmuscle myosin. J Biol Chem. 2001;276:30293-30300.
45. Kummalue T, Lou J, Friedman AD. Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein. Mol Cell Biol. 2002;22:8278-8291.
46. Beausoleil SA, Jedrychowski M, Schwartz D, et al. Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A. 2004;101:12130-12135.
47. Lutterbach B, Hou Y, Durst KL, Hiebert SW. The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci U S A. 1999;96:12822-12827.
48. Imai Y, Kurokawa M, Yamaguchi Y, et al. The corepressor mSin3A regulates phosphorylationinduced activation, intranuclear location, and stability of AML1. Mol Cell Biol. 2004;24:1033-1043.
49. Biggs JR, Peterson LF, Zhang Y, Kraft AS, Zhang DE. AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol. 2006;26:7420-7429.
50. Wijmenga C, Gregory PE, Hajra A, et al. Core binding factor beta-smooth muscle myosin heavy chain chimeric protein involved in acute myeloid leukemia forms unusual nuclear rod-like structures in transformed NIH 3T3 cells. Proc Natl Acad Sci U S A. 1996;93:1630-1635.
51. Adya N, Stacy T, Speck NA, Liu PP. The leukemic protein core binding factor beta (CBFbeta)-smooth-muscle myosin heavy chain sequesters CBFalpha2 into cytoskeletal filaments and aggregates. Mol Cell Biol. 1998;18:7432-7443.
52. Isono K, Nemoto K, Li Y, et al. Overlapping roles for homeodomain-interacting protein kinases hipk1 and hipk2 in the mediation of cell growth in response to morphogenetic and genotoxic signals. Mol Cell Biol. 2006;26:2758-2771.
53. Calzado MA, Renner F, Roscic A, Schmitz ML. HIPK2: a versatile switchboard regulating the transcription machinery and cell death. Cell Cycle. 2007;6:139-143.
54. Li XL, Arai Y, Harada H, et al. Mutations of the HIPK2 gene in acute myeloid leukemia and myelodysplastic syndrome impair AML1- and p53-mediated transcription. Oncogene. 2007;28:28.
55. Hofmann TG, Moller A, Sirma H, et al. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat Cell Biol. 2002;4:1-10.
56. D'Orazi G, Cecchinelli B, Bruno T, et al. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol. 2002;4:11-19.
57. Britos-Bray M, Ramirez M, Cao W, et al. CBFbeta-SMMHC, expressed in M4eo acute myeloid leukemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNAdamaging agents. Blood. 1998;92:4344-4352.